PARKERVISION INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PARKERVISION INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $25.00M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $925.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $144.0K | Mar 28, 2023 |
| FY2018 | Dec 31, 2018 | $135.0K | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $100.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.06M | Mar 29, 2018 |
| FY2014 | Dec 31, 2014 | $0 | Mar 16, 2015 |
| FY2014 | Sep 30, 2014 | $0 | Mar 16, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($199.0K) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($229.0K) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $24.77M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $915.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $139.0K | Mar 28, 2023 |
| FY2020 | Dec 31, 2019 | ($5.0K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.10M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($100.0K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.72M | Mar 29, 2018 |
| FY2015 | Dec 31, 2015 | ($1.0K) | Mar 30, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.43M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($14.47M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $9.52M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($9.81M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($12.33M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($19.58M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($9.45M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($20.87M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($19.26M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($21.51M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $334.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.88M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $4.34M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.34M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $4.14M | Mar 30, 2017 |
| FY2016 | Dec 31, 2014 | $7.05M | Mar 30, 2017 |
| FY2015 | Dec 31, 2013 | $10.41M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $8.45M | Mar 16, 2015 |
| FY2013 | Dec 31, 2011 | $8.42M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $8.88M | Mar 18, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.61M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $4.26M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $14.74M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $7.77M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.09M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $10.66M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $7.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $10.43M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $14.06M | Apr 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.14M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($3.22M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $10.79M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($2.96M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($7.70M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($4.78M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($3.37M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($10.30M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($14.06M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($14.36M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.0K | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $2.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $4.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.0K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $252.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.0K | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.36M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $5.88M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $4.02M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.75M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $3.44M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.46M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $3.93M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.33M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $8.91M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $8.58M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.46M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $52.29M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $43.54M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $52.44M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $48.22M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $48.28M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $37.02M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $31.64M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $20.15M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $16.70M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.10M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($46.41M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | ($39.52M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | ($50.69M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | ($44.78M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($43.82M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | ($33.10M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | ($25.31M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($11.24M) | Apr 14, 2020 |
| FY2017 | Dec 31, 2016 | ($8.12M) | Mar 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($455.61M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($448.18M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($433.71M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($443.23M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($433.41M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($421.36M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($401.78M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($392.29M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($371.42M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($352.16M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.36M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $4.92M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $2.56M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $109.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.03M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.63M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $57.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.53M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $354.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $258.0K | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.0K | Mar 23, 2026 |
| FY2024 | Dec 31, 2024 | $340.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2023 | $474.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2022 | $612.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2021 | $703.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2020 | $1.02M | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | $2.33M | Apr 14, 2020 |
| FY2018 | Dec 31, 2018 | $3.24M | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | $825.0K | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 143.16M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 113.97M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 87.68M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 81.25M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 76.99M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 58.59M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 34.10M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 28.68M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 21.22M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 13.18M | Mar 29, 2018 |